文献速递认知障碍与痴呆

机器学习预测阿尔茨海默病临床试验认知下降

A Machine Learning Approach to Predict Cognitive Decline in Alzheimer Disease Clinical Trials.
PubMed 文献 · Neurology · 2025-03-25

模型在内部和外部验证中均显示高敏感度、中等特异度,阳性预测值分别至少高于基线患病率11%和15%。

要点

  • 机器学习模型可识别80周内不太可能出现认知下降的安慰剂组患者。
  • 内部验证中模型阳性预测值至少高于试验末CMCD基线患病率11%。
  • ADNI外部验证中模型阳性预测值至少高于该队列基线患病率15%。

核心结论

  • 预测模型有潜力通过基于预期认知下降的选择性纳入和排除标准来改进AD试验设计。
  • 此类预测模型需在不同AD临床试验数据中进一步验证。

研究设计与样本

  • 在EXPEDITION3安慰剂样本的70%中采用5折交叉验证训练机器学习分类器,使用人口学、APOE基因型、神经心理测试和 volumetric MRI 生物标志物组合。
  • 训练模型用于内部验证样本和外部匹配ADNIAD样本的分类。

主要发现

  • EXPEDITION3独立验证样本中所有模型显示高敏感度和中等特异度,阳性预测值至少高于试验末CMCD基线患病率11%。
  • ADNIAD外部验证中模型同样显示高敏感度、中等特异度和阳性预测值至少高于ADNIAD基线患病率15%。

局限性

  • 原文述预测模型需在不同AD临床试验数据中进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: Among the participants of Alzheimer disease (AD) treatment trials, 40% do not show cognitive decline over 80 weeks of follow-up. Identifying and excluding these individuals can increase power to detect treatment effects. We aimed to develop machine learning-based predictive models to identify persons unlikely to show decline on placebo treatment over 80 weeks. METHODS: We used the data from the placebo arm of EXPEDITION3 AD clinical trial and a subpopulation from the Alzheimer's Disease Neuroimaging Initiative (ADNI). Participants in the EXPEDITION3 trial were patients with mild dementia and biomarker evidence of amyloid burden. For this study, participants were identified as those who demonstrated clinically meaningful cognitive decline (CMCD) or cognitively stable (CS) at final visit of the trial (week 80). Machine learning-based classifiers were trained to classify participants into CMCD vs CS groups using combinations of demographics, APOE genotype, neuropsychological tests, and biomarkers (volumetric MRI). The results were developed in 70% of the EXPEDITION3 placebo sample using 5-fold cross-validation. Trained models were then used to classify the participants in an internal validation sample and an external matched sample ADNIAD. RESULTS: Eight hundred ninety-four of the 1,072 participants in the placebo arm of the EXPEDITION3 trial had necessary follow-up data, who were on average aged 72.7 (±7.7) years and 59% female. 55.8% of those participants showed CMCD (∼2 years younger than those without) at the final visit. In the independent validation sample within the EXPEDITION3 data, all the models showed high sensitivity and modest specificity. Positive predictive values (PPVs) of models were at least 11% higher than base prevalence of CMCD observed at the end of the trial. The subset of matched ADNI participants (ADNIAD, N = 105) were aged 74.5 (±6.4) years and 46% female. The models that were validated in ADNIAD also showed high sensitivity, modest specificity, and PPVs of at least 15% higher than the base prevalence in ADNIAD. DISCUSSION: Our results indicate that predictive models have the potential to improve the design of AD trials through selective inclusion and exclusion criteria based on expected cognitive decline. Such predictive models need further validation across data from different AD clinical trials.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Nallapu BT, Petersen KK, Qian T, et al. A Machine Learning Approach to Predict Cognitive Decline in Alzheimer Disease Clinical Trials. Neurology. 2025. PMID: 40132145. doi:10.1212/WNL.0000000000213490

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。